PTLA Portola Pharmaceuticals Inc.

+0.86  (+3%)
Previous Close 30.15
Open 30.33
Price To Book 12.5
Market Cap 2060119146
Shares 66,434,026
Volume 1,152,355
Short Ratio
Av. Daily Volume 1,877,712

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval noted June 23, 2017.
Bevyxxa (betrixaban)
Venous thromboembolism (VTE) Prevention
Phase 2 updated data due at ASH December 2018 noted ORR 34%; 27% CR and in the PTCL cohort ORR 26%; 7% CR.
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
Prior Approval Supplement (PAS) FDA Approval announced December 31, 2018.
Factor Xa inhibitor reversal agent

Latest News

  1. Will Portola Pharmaceuticals (PTLA) Report Negative Earnings Next Week? What You Should Know
  2. Report: Exploring Fundamental Drivers Behind Crocs, Portola Pharmaceuticals, ANSYS, Alpha and Omega Semiconductor, PetMed Express, and MYOS RENS Technology — New Horizons, Emerging Trends, and Upcoming Developments
  3. See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
  4. Portola Pharmaceuticals Announces Full Results from the ANNEXA-4 Study of the Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Life-Threatening Bleeding
  5. Is There An Opportunity With Portola Pharmaceuticals, Inc.’s (NASDAQ:PTLA) 22.17% Undervaluation?
  6. Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on Friday, March 1, 2019
  7. Portola Pharmaceuticals to Present Full Results from the ANNEXA-4 Study of Andexxa During a Late-Breaking Oral Presentation at the International Stroke Conference 2019
  8. Portola Pharmaceuticals Appoints Sheldon Koenig as Chief Commercial Officer
  9. Why Portola Pharmaceuticals Rose 8.09% on January 4
  10. Take Profits on This Pharma Stock
  11. Portola Up as Large-Scale Andexxa Production Gets FDA Nod
  12. Portola stock shoots higher after FDA approval
  13. U.S. Food and Drug Administration Approves Portola Pharmaceuticals’ Prior Approval Supplement for Andexxa® Generation 2 Manufacturing Process
  14. Portola Pharmaceuticals to Webcast Corporate Update on January 8, 2019
  15. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA): Is Breakeven Near?
  16. Here's Why Portola Pharmaceuticals Fell 11% Today
  17. Is Portola Pharmaceuticals Inc (PTLA) A Good Stock To Buy?
  18. Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya
  19. Why Portola Pharmaceuticals’ Stock Price Is Plummeting Today